Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 20:20    source : Investors.biomarin.com    save search
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis
Published: 2022-01-09 (Crawled : 20:20) - investors.biomarin.com
BMRN | $92.01 2.82% 710K twitter stocktwits trandingview |
Health Technology
 | | O: 3.38% H: 1.08% C: -3.11%
gene therapy phase 3
Gainers vs Losers
87% 13%

Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M twitter stocktwits trandingview |

AGBA | $2.74 119.2% 52M twitter stocktwits trandingview |
Finance
CZOO | $9.07 81.76% 22M twitter stocktwits trandingview |

EDBL | News | $6.56 74.47% 1.8M twitter stocktwits trandingview |

MTC | $2.21 41.67% 5.6M twitter stocktwits trandingview |
Technology Services
OPRT | News | $3.12 38.67% 11M twitter stocktwits trandingview |
Finance
PALI | $6.59 33.67% 23M twitter stocktwits trandingview |
Manufacturing
VNRX | $0.7945 32.42% 3.1M twitter stocktwits trandingview |
Health Technology
MLEC | $1.81 29.29% 2.8M twitter stocktwits trandingview |
n/a
BTCM | $3.45 27.78% 640K twitter stocktwits trandingview |
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.